5-bromo-2-(2-pyrrolidin-1-yl-ethoxy)-pyrimidine | 617703-45-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-bromo-2-(2-pyrrolidin-1-yl-ethoxy)-pyrimidine
• 英文别名: 5-bromo-2-(2-pyrrolidin-1-ylethoxy)pyrimidine
• CAS: 617703-45-4
• 化学式: C₁₀H₁₄BrN₃O
• 分子量: 272.145
• InChiKey: DQEXXZUJQBREPE-UHFFFAOYSA-N

物化性质

• 沸点：
  376.5±48.0 °C(Predicted)
• 密度：
  1.444±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(4-chloro-phenyl)-2-ethynyl-pyridine 、 5-bromo-2-(2-pyrrolidin-1-yl-ethoxy)-pyrimidine 在 四(三苯基膦)钯 copper(l) iodide 、 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 0.33h， 以6.6%的产率得到5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-pyrimidine
  参考文献：
  名称：

  [DE] NEUE ALKIN-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL
  [EN] NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS
  [FR] NOUVEAUX COMPOSES ALKINE A ACTIVITE ANTAGONISTE CONTRE MCH ET MEDICAMENTS CONTENANT CES COMPOSES

  摘要：

  本发明涉及一般式（I）的炔基化合物，其中基团和残基A、B、W、X、Y、Z、R1和R2具有权利要求1中所述的含义。此外，该发明涉及含有至少一种本发明炔基化合物的药物。由于MCH受体拮抗活性，本发明药物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。

  公开号：

  WO2004039780A1
• 作为产物：
  描述：

  5-溴-2-氯嘧啶 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.25h， 以71.1%的产率得到5-bromo-2-(2-pyrrolidin-1-yl-ethoxy)-pyrimidine
  参考文献：
  名称：

  [DE] NEUE ALKIN-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL
  [EN] NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS
  [FR] NOUVEAUX COMPOSES ALKINE A ACTIVITE ANTAGONISTE CONTRE MCH ET MEDICAMENTS CONTENANT CES COMPOSES

  摘要：

  本发明涉及一般式（I）的炔基化合物，其中基团和残基A、B、W、X、Y、Z、R1和R2具有权利要求1中所述的含义。此外，该发明涉及含有至少一种本发明炔基化合物的药物。由于MCH受体拮抗活性，本发明药物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。

  公开号：

  WO2004039780A1

文献信息

• [EN] BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DERIVES DE BENZAMIDE UTILES EN TANT QU'INHIBITEURS D'HISTONE DEACETYLASE
  申请人：ASTRAZENECA AB

  公开号：WO2003087057A1

  公开（公告）日：2003-10-23

  The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase.

  本发明涉及一种公式(I)的化合物，其中环A是杂环；m为0-4，每个R1是如羟基、卤素、三氟甲基和腈的基团；R2是卤素，n为0-2；每个R4是如羟基、卤素、三氟甲基和腈的基团；p为0-4；R3是氨基或羟基；或其药物可接受的盐或体内可水解的酯或酰胺及其制备过程，包含它们的药物组合物以及它们在治疗由组蛋白脱乙酰酶介导的疾病或医疗条件中的用途。
• Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040209865A1

  公开（公告）日：2004-10-21

  The present invention relates to alkyne compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 and R 2 have the meanings given in claim 1 . The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的炔烃化合物 1 其中基团和残基A、B、W、X、Y、Z、R 1 和R 2 具有权利要求中给出的含义。本发明还涉及含有根据本发明至少一种炔烃的药物组合物。鉴于它们的MCH受体拮抗活性，根据本发明的药物组合物适用于治疗代谢紊乱和/或进食紊乱，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。
• Benzamide derivatives useful as histone deacetylase inhibitors
  申请人：Stokes Sophie Elizabeth Elaine

  公开号：US20050171103A1

  公开（公告）日：2005-08-04

  The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R 1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R 2 is, halo and n is 0-2; and each R 4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R 3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase.

  本发明涉及一种化合物，其化学式为（I），其中环A为杂环基；m为0-4，每个R1是羟基、卤素、三氟甲基和氰基等基团；R2为卤素，n为0-2；每个R4是羟基、卤素、三氟甲基和氰基等基团；p为0-4；R3为氨基或羟基；或其药学可接受的盐或体内可水解的酯或酰胺，以及制备它们的过程，含有它们的制药组合物以及它们在治疗组织脱乙酰化酶介导的疾病或医学状况中的用途。
• BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS
  申请人：Stokes Elaine Sophie Elizabeth

  公开号：US20090029991A1

  公开（公告）日：2009-01-29

  The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R 1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R 2 is halo and n is 0-2; and each R 4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R 3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by histone deacetylase.

  本发明涉及式（I）的化合物，其中环A是杂环基；m为0-4，每个R1是羟基、卤素、三氟甲基和氰基等基团；R2是卤素，n为0-2；每个R4是羟基、卤素、三氟甲基和氰基等基团；p为0-4；R3是氨基或羟基；或其药学上可接受的盐或体内可水解的酯或酰胺，其制备方法，含有它们的制药组合物以及它们在通过组蛋白去乙酰化酶介导的疾病或医学情况的治疗中的应用。
• ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS
  申请人：Stenkamp Dirk

  公开号：US20090069282A1

  公开（公告）日：2009-03-12

  The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R 1 and R 2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的炔化合物，其中A、B、W、X、Y、Z、R1和R2的基团和残基具有权利要求1中给出的含义。本发明还涉及包含至少一种根据本发明的炔烃的制药组合物。鉴于它们的MCH受体拮抗活性，根据本发明的制药组合物适用于治疗代谢性疾病和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。